Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Merritt who wrote (42638)	1/8/1999 2:36:00 AM
From: Peter Singleton	Read Replies (1) \| Respond to of 132070

ok, I'm finally caught up, and am at the end of the thread. btw, Mike (aka Wm M) that Global Financial Data article on 1929 etc was fascinating. Merritt, Scripps has tremendous technology with integrins. big implications for anti-angiogenesis and a bunch of other stuff. Peter

To: Merritt who wrote (42638)	1/8/1999 10:11:00 AM
From: Ilaine	Respond to of 132070

Hi Merritt, no, I had not noticed the article, but I wonder why it was linked to Celgene discussion. Celgene is working on (among other things) tumor necrosis factor-alpha (TNF-a) inhibitors as a treatment for autoimmune diseases, they have a license from Rockefeller University for its use patent on thalidomide for TNF-a inhibition. As you know, thalidomide has been around since the 50's, you and I are old enough to remember thalidomide babies, but it has been used to treat Hansen's disease, and is being tested on cancer, and Rockefeller got a use patent a couple of years ago. The research by Scripps Research Institute is on an anti-angiogenesis compound. I don't think Celgene is working on anti-angiogenesis. I find the concept of anti-angiogenesis very interesting, you no doubt remember Entremed, that is what they are working on, as a cure for cancer, but I am not up to date on that. I did a patent search on Scripps Institute and angiogenesis, they do have a patent on the compound, but I see that a lot of companies have patents on anti-angiogenesis compounds.

To: Merritt who wrote (42638)	1/8/1999 5:18:00 PM
From: Ilaine	Read Replies (2) \| Respond to of 132070

Hi Merritt, I took a closer look at Celgene and Entremed, they announced yesterday that Celgene would take over Entremed's ongoing clinical trials using thalidomide. I then looked at the NIH site on ongoing clinical trials and was surprised to learn that Entremed had testing thalidomide as an anti-angiogenesis drug. It really is weird to think of thalidomide as the new wonder drug, the birth defects it causes are so horrific, but I would expect an oncology drug to cause horrible birth defects, so maybe it isn't so strange, after all.